Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 8, 2026
Nkarta, Inc. (NKTX)
A forensic read on Nkarta, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
0.5
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-30.9%
ROE
$252M
Market cap
Nkarta, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 0.5, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-28%Return on invested capital.Return on invested capital is -28% in the latest fiscal year and slipping from -23% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+19.3%/yrShare-count dilution.Diluted share count changed +70% over the last 3 years to FY2025 (+19.3%/yr). The count is GROWING — existing holders are being diluted. That's ~19.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~41%.
Key fundamentals
Free Cash Flow$-89.9M
Return on Equity-33.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Nkarta, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about NKTX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown